Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 7;16(1):26.
doi: 10.1186/s12977-019-0488-8.

BLV: lessons on vaccine development

Alejandro Abdala  1 , Irene Alvarez  2 , Hélène Brossel  3 , Luis Calvinho  1 , Hugo Carignano  2 , Lautaro Franco  2 , Hélène Gazon  3 , Christelle Gillissen  3 , Malik Hamaidia  3 , Clotilde Hoyos  3 , Jean-Rock Jacques  3 , Thomas Joris  3 , Florent Laval  3 , Marcos Petersen  2 , Florent Porquet  3 , Natalia Porta  2 , Vanesa Ruiz  2 , Roghaiyeh Safari  3 , Guillermo Suárez Archilla  1 , Karina Trono  2 , Luc Willems  4   5
Affiliations
Review

BLV: lessons on vaccine development

Alejandro Abdala et al. Retrovirology. .

Abstract

Vaccination against retroviruses is a challenge because of their ability to stably integrate into the host genome, undergo long-term latency in a proportion of infected cells and thereby escape immune response. Since clearance of the virus is almost impossible once infection is established, the primary goal is to achieve sterilizing immunity. Besides efficacy, safety is the major issue since vaccination has been associated with increased infection or reversion to pathogenicity. In this review, we discuss the different issues that we faced during the development of an efficient vaccine against bovine leukemia virus (BLV). We summarize the historical failures of inactivated vaccines, the efficacy and safety of a live-attenuated vaccine and the economical constraints of further industrial development.

Keywords: BLV; HTLV; Leukemia; Retrovirus; Vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Barez PY, de Brogniez A, Carpentier A, Gazon H, Gillet N, Gutierrez G, et al. Recent advances in BLV research. Viruses. 2015;7:6080–6088. doi: 10.3390/v7112929. - DOI - PMC - PubMed
    1. Gillet N, Florins A, Boxus M, Burteau C, Nigro A, Vandermeers F, et al. Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human. Retrovirology. 2007;4:18. doi: 10.1186/1742-4690-4-18. - DOI - PMC - PubMed
    1. Aida Y, Murakami H, Takahashi M, Takeshima S-N. Mechanisms of pathogenesis induced by bovine leukemia virus as a model for human T-cell leukemia virus. Front Microbiol. 2013;4:328. doi: 10.3389/fmicb.2013.00328. - DOI - PMC - PubMed
    1. Burny A, Bruck C, Cleuter V, Couez D, Deschamps J, Ghysdael J, et al. Bovine Leukemia Virus, a versatile agent with various pathogenic effects in various animal species. Cancer Res. 1985;45(suppl):4578–4583. - PubMed
    1. Norby B, Bartlett PC, Byrem TM, Erskine RJ. Effect of infection with bovine leukemia virus on milk production in Michigan dairy cows. J Dairy Sci. 2016;99:1–10. doi: 10.3168/jds.2015-10089. - DOI - PubMed

Publication types

MeSH terms